Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer

BACKGROUND: Mutation in the tumor suppressor gene TP53 is an early event in the development of high-grade serous (HGS) ovarian cancer and is identified in more than 96 % of HGS cancer patients. APR-246 (PRIMA-1(MET)) is the first clinical-stage compound that reactivates mutant p53 protein by refoldi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fransson, Åsa, Glaessgen, Daria, Alfredsson, Jessica, Wiman, Klas G., Bajalica-Lagercrantz, Svetlana, Mohell, Nina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868029/
https://www.ncbi.nlm.nih.gov/pubmed/27179933
http://dx.doi.org/10.1186/s13048-016-0239-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868029/
https://www.ncbi.nlm.nih.gov/pubmed/27179933
http://dx.doi.org/10.1186/s13048-016-0239-6

Ejemplares similares